Pull to refresh
Logo
Daily Brief
Following Why Ranks Sign Up
Hui Zhou

Hui Zhou

Chief R&D Officer, Oncology, Innovent Biologics

Appears in 1 story

Notable Quotes

Patients with advanced gastric cancer generally have poor prognosis after initial treatment, with median survival around six months.

Stories

First CLDN18.2 antibody-drug conjugate reaches regulatory review for gastric cancer

New Capabilities

Leading the drug's development program

Advanced gastric cancer that returns after treatment usually kills within about six months. On June 4, 2026, Chinese biotech Innovent Biologics said its drug had slowed that clock in a late-stage trial.

Updated 2 hours ago